Table 1.
Open in new tab

Basic Demographic Indicators and Baseline and Final Seroprevalence of Anti-polio Antibodies, Including Median Titer and 95% CI

Arm A
(IPV Only)		Arm B
(IPV + bOPV)		Arm C
(No Vaccine Prior to tOPV)
Demographic indicators
 No. female subjects/total subjects (%)47/113 (42%)65/116 (56%)51/104 (49%)
 Age at Enrollment, in months (median IQR)6.2 (5.6–6.7)6.2 (5.4–7)2.5 (2.2–2.8)
 Weight, in kgs (median IQR)8.2 (7.7–8.9)7.9 (7.3–8.8)5.7 (5.2–6.5)
Baseline seroprevalence
 Poliovirus Type 1, n/N (%, 95% CI)8/113
(7%, 3–13%)		3/116
(3%, 0–7%)		41/104
(39%, 30–49%)
 Titer, as median (95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
 Poliovirus Type 2, n/N (%, 95% CI)6/113
(5%, 2–11%)		4/116
(3%, 1–9%)		37/104
(36%, 26–46%)
 Titer (median, 95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
 Poliovirus Type 3, n/N (%, 95% CI)6/113
(5%, 2–11%)		1/115
(1%, 0–5%)		10/103
(10%, 5–17%)
 Titer, as median (95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
Final seroprevalence
 Poliovirus Type 1, n/N (%, 95% CI)109/113
(96%, 91–99%)		109/116
(94%, 88–98%)		101/104
(97%, 92–99%)
 Titer, as median (95% CI)283, 179–508897, 713–1130449, 283–566
 Poliovirus Type 2, n/N (%, 95% CI)109/113
(96%, 91–99%)		105/116
(91%, 84–95%)		99/104
(95%, 89–98%)
 Titer (median, 95% CI)357, 225–449320, 225–357225, 179–283
 Poliovirus Type 3, n/N (%, 95% CI)108/112
(96%, 91–99%)		105/116
(91%, 84–95%)		100/104
(96%, 90–99%)
 Titer, as median (95% CI)805 (566–1130)449 (357–566)283 (142–449)
Arm A
(IPV Only)		Arm B
(IPV + bOPV)		Arm C
(No Vaccine Prior to tOPV)
Demographic indicators
 No. female subjects/total subjects (%)47/113 (42%)65/116 (56%)51/104 (49%)
 Age at Enrollment, in months (median IQR)6.2 (5.6–6.7)6.2 (5.4–7)2.5 (2.2–2.8)
 Weight, in kgs (median IQR)8.2 (7.7–8.9)7.9 (7.3–8.8)5.7 (5.2–6.5)
Baseline seroprevalence
 Poliovirus Type 1, n/N (%, 95% CI)8/113
(7%, 3–13%)		3/116
(3%, 0–7%)		41/104
(39%, 30–49%)
 Titer, as median (95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
 Poliovirus Type 2, n/N (%, 95% CI)6/113
(5%, 2–11%)		4/116
(3%, 1–9%)		37/104
(36%, 26–46%)
 Titer (median, 95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
 Poliovirus Type 3, n/N (%, 95% CI)6/113
(5%, 2–11%)		1/115
(1%, 0–5%)		10/103
(10%, 5–17%)
 Titer, as median (95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
Final seroprevalence
 Poliovirus Type 1, n/N (%, 95% CI)109/113
(96%, 91–99%)		109/116
(94%, 88–98%)		101/104
(97%, 92–99%)
 Titer, as median (95% CI)283, 179–508897, 713–1130449, 283–566
 Poliovirus Type 2, n/N (%, 95% CI)109/113
(96%, 91–99%)		105/116
(91%, 84–95%)		99/104
(95%, 89–98%)
 Titer (median, 95% CI)357, 225–449320, 225–357225, 179–283
 Poliovirus Type 3, n/N (%, 95% CI)108/112
(96%, 91–99%)		105/116
(91%, 84–95%)		100/104
(96%, 90–99%)
 Titer, as median (95% CI)805 (566–1130)449 (357–566)283 (142–449)

Abbreviations: bOPV, bivalent oral poliovirus vaccine; CI, confidence interval; IPV, inactivated poliovirus vaccine; IQR, interquartile range; tOPV, trivalent oral poliovirus vaccine.

Table 1.
Open in new tab

Basic Demographic Indicators and Baseline and Final Seroprevalence of Anti-polio Antibodies, Including Median Titer and 95% CI

Arm A
(IPV Only)		Arm B
(IPV + bOPV)		Arm C
(No Vaccine Prior to tOPV)
Demographic indicators
 No. female subjects/total subjects (%)47/113 (42%)65/116 (56%)51/104 (49%)
 Age at Enrollment, in months (median IQR)6.2 (5.6–6.7)6.2 (5.4–7)2.5 (2.2–2.8)
 Weight, in kgs (median IQR)8.2 (7.7–8.9)7.9 (7.3–8.8)5.7 (5.2–6.5)
Baseline seroprevalence
 Poliovirus Type 1, n/N (%, 95% CI)8/113
(7%, 3–13%)		3/116
(3%, 0–7%)		41/104
(39%, 30–49%)
 Titer, as median (95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
 Poliovirus Type 2, n/N (%, 95% CI)6/113
(5%, 2–11%)		4/116
(3%, 1–9%)		37/104
(36%, 26–46%)
 Titer (median, 95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
 Poliovirus Type 3, n/N (%, 95% CI)6/113
(5%, 2–11%)		1/115
(1%, 0–5%)		10/103
(10%, 5–17%)
 Titer, as median (95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
Final seroprevalence
 Poliovirus Type 1, n/N (%, 95% CI)109/113
(96%, 91–99%)		109/116
(94%, 88–98%)		101/104
(97%, 92–99%)
 Titer, as median (95% CI)283, 179–508897, 713–1130449, 283–566
 Poliovirus Type 2, n/N (%, 95% CI)109/113
(96%, 91–99%)		105/116
(91%, 84–95%)		99/104
(95%, 89–98%)
 Titer (median, 95% CI)357, 225–449320, 225–357225, 179–283
 Poliovirus Type 3, n/N (%, 95% CI)108/112
(96%, 91–99%)		105/116
(91%, 84–95%)		100/104
(96%, 90–99%)
 Titer, as median (95% CI)805 (566–1130)449 (357–566)283 (142–449)
Arm A
(IPV Only)		Arm B
(IPV + bOPV)		Arm C
(No Vaccine Prior to tOPV)
Demographic indicators
 No. female subjects/total subjects (%)47/113 (42%)65/116 (56%)51/104 (49%)
 Age at Enrollment, in months (median IQR)6.2 (5.6–6.7)6.2 (5.4–7)2.5 (2.2–2.8)
 Weight, in kgs (median IQR)8.2 (7.7–8.9)7.9 (7.3–8.8)5.7 (5.2–6.5)
Baseline seroprevalence
 Poliovirus Type 1, n/N (%, 95% CI)8/113
(7%, 3–13%)		3/116
(3%, 0–7%)		41/104
(39%, 30–49%)
 Titer, as median (95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
 Poliovirus Type 2, n/N (%, 95% CI)6/113
(5%, 2–11%)		4/116
(3%, 1–9%)		37/104
(36%, 26–46%)
 Titer (median, 95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
 Poliovirus Type 3, n/N (%, 95% CI)6/113
(5%, 2–11%)		1/115
(1%, 0–5%)		10/103
(10%, 5–17%)
 Titer, as median (95% CI)<8 (<8–<8)<8 (<8–<8)<8 (<8–<8)
Final seroprevalence
 Poliovirus Type 1, n/N (%, 95% CI)109/113
(96%, 91–99%)		109/116
(94%, 88–98%)		101/104
(97%, 92–99%)
 Titer, as median (95% CI)283, 179–508897, 713–1130449, 283–566
 Poliovirus Type 2, n/N (%, 95% CI)109/113
(96%, 91–99%)		105/116
(91%, 84–95%)		99/104
(95%, 89–98%)
 Titer (median, 95% CI)357, 225–449320, 225–357225, 179–283
 Poliovirus Type 3, n/N (%, 95% CI)108/112
(96%, 91–99%)		105/116
(91%, 84–95%)		100/104
(96%, 90–99%)
 Titer, as median (95% CI)805 (566–1130)449 (357–566)283 (142–449)

Abbreviations: bOPV, bivalent oral poliovirus vaccine; CI, confidence interval; IPV, inactivated poliovirus vaccine; IQR, interquartile range; tOPV, trivalent oral poliovirus vaccine.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close